Wednesday, May 8, 2019

GV, Alphabet Inc's venture capital arm, led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.


from Reuters: Health News https://reut.rs/2VOMl3J

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner